Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INI-4001 + cemiplimab
- Development stage
- Unknown
- Lead developer
- Inimmune
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Subcutaneous
01
Overview
**INI-4001 + cemiplimab** is an investigational combination therapy for advanced solid tumors. INI-4001 is a novel small molecule agonist of Toll-like receptor 7 and 8 (TLR7/8) optimized for nanoparticle delivery, developed by Inimmune. It is designed to activate innate immune responses, increasing antigen presenting cell (APC) activity, IFNα production, and stimulating CD8 T cell antitumor activity. Cemiplimab is an approved monoclonal antibody checkpoint inhibitor targeting PD-1, enhancing adaptive immune responses against tumors. The combination aims to leverage both innate and adaptive immune system activation in patients with advanced solid tumors who progress or have stable disease after initial INI-4001 monotherapy.
- Other names
- INI-4001 + Libtayo
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TLR8 (Toll-like receptor 8)TLR7 (Toll-like receptor 7)
Beyond the preview
Go deeper on INI-4001 + cemiplimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INI-4001 + cemiplimab.